Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Anthony Hamlett"'
Autor:
Philip Campbell, Jennifer Whalen, Tycel Phillips, Franck Morschhauser, Maciej Kaźmierczak, Anna Schmitt, Aristeidis Chaidos, John Radford, Deyaa Adib, Sarit Assouline, Wojciech Jurczak, Gandhi Damaj, Hervé Tilly, Connie Lee Batlevi, Beth Kamp, Vincent Ribrag, Pam McKay, Stephen Opat, Anthony Hamlett, Michael Dickinson, Gilles Salles
Publikováno v:
Blood. 136:47-49
Background: Tazemetostat, a first-in-class, oral, enhancer of zeste homolog 2 (EZH2) inhibitor was recently approved by the US Food and Drug Administration in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after demonstrating single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::522e366c95281ae67d2d8282745c1abb
https://doi.org/10.1182/blood-2020-137245
https://doi.org/10.1182/blood-2020-137245
Autor:
Heather O'Connor, Jay Yang, John M. Pagel, Connie Lee Batlevi, Pamela McKay, Anthony Hamlett, Loretta J. Nastoupil, Jennifer E Amengual, Deyaa Adib, David Andorsky, Tycel Phillips, Franck Morschhauser, John P. Leonard, Philip Campbell, Steven I. Park
Publikováno v:
Blood. 138:2207-2207
Background: Tazemetostat (TAZ), an enhancer of zeste homolog 2 inhibitor, showed antitumor activity as monotherapy in patients with wild-type and mutant EZH2 relapsed or refractory (R/R) follicular lymphoma (FL) who received ≥2 prior lines of thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f74ada13463b3f240ea4198b2d2f386c
https://doi.org/10.1182/blood-2021-148199
https://doi.org/10.1182/blood-2021-148199
Autor:
Melinda S. Merchant, James L. Chen, Jessica Ainscough, Coya Tapia, Victoria S. Chua, Robin L. Jones, Sant P. Chawla, Melissa Amber Burgess, Anthony Hamlett, Rashmi Chugh, Gerald Steven Falchook
Publikováno v:
Journal of Clinical Oncology. 39:11563-11563
11563 Background: ES is a rare, aggressive subtype of STS for which cytotoxic chemotherapy has limited effectiveness. TAZ, an FDA-approved EZH2 inhibitor, has shown single-agent clinical activity and a favorable safety profile in patients with metast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7470ca5d2df10ca2461c1764ae321f6a
https://doi.org/10.1200/jco.2021.39.15_suppl.11563
https://doi.org/10.1200/jco.2021.39.15_suppl.11563
Autor:
Laura Sierra, Tom Zimmerman, Shiraj Sen, Melinda S. Merchant, Jessica Ainscough, Jay Yang, Meredith Ann McKean, Anthony Hamlett, Sant P. Chawla
Publikováno v:
Journal of Clinical Oncology. 38:TPS11573-TPS11573
TPS11573 Background: Epithelioid sarcoma (ES) is characterized by loss of inhibitor of integrase 1 (INI1), allowing enhancer of zeste homologue 2 (EZH2) to repress cell differentiation and promote tumorigenesis. Tazemetostat (TAZ) is an EZH2 inhibito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0dda961107a4c7dc4f0ebc84a063d378
https://doi.org/10.1200/jco.2020.38.15_suppl.tps11573
https://doi.org/10.1200/jco.2020.38.15_suppl.tps11573
Autor:
Lawrence Karsh, Deyaa Adib, Daniel Saltzstein, Arash Rezazadeh, Thomas Bradley, Anthony Hamlett, Ashley E. Ross, Evren Kocabas Argon, Wassim Abida, Jeanie Tang
Publikováno v:
Journal of Clinical Oncology. 38:TPS255-TPS255
TPS255 Background: The histone methyltransferase EZH2 is overexpressed in many cancers. In prostate cancer (PC), EZH2 inhibition may reverse acquired resistance to androgen inhibitors (AIs). Pts may initially respond to AIs, but pts who progress have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::910335a32187dbdd9aa3e3d88fcf6718
https://doi.org/10.1200/jco.2020.38.6_suppl.tps255
https://doi.org/10.1200/jco.2020.38.6_suppl.tps255
Autor:
Cristina Gasparetto, Craig E. Cole, Marcelo Capra, Pekka Anttila, Sara Bringhen, Vladimir I. Vorobyev, Vania Hungria, Meletios A. Dimopoulos, Eduardo Yanez Ruiz, Anthony Hamlett, Jianyun Yin, Matthew W Jenner, Michele Cavo, Ravi Vij
Publikováno v:
Blood. 132:155-155
Background: Isatuximab (ISA) targets CD38-expressing tumor cells through a combination of activities, including antibody-dependent cellular cytotoxicity, direct pro-apoptotic activity, and complement-dependent cytotoxicity. A phase I study evaluating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::609f04c378410c32bb725614767e92b4
https://doi.org/10.1182/blood-2018-155
https://doi.org/10.1182/blood-2018-155
Publikováno v:
Drug Information Journal. 36:855-864
Finding the right dose or the right range of doses is one of the most important objectives in the clinical development program of a new drug. In designing early Phase 2 dose response studies, one critical question is: “What spacing should be used b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80d062a8fc41f0e8994802af7c4714ad
https://doi.org/10.1177/009286150203600414
https://doi.org/10.1177/009286150203600414
Autor:
Pisit, Pitukcheewanont, Paul, Desrosiers, Joel, Steelman, Robert, Rapaport, John S, Fuqua, Nerissa C, Kreher, Anthony, Hamlett
Publikováno v:
Pediatric endocrinology reviews : PER. 5
The GHMonitor observational registry collates data on pediatric subjects receiving Saizen (recombinant human growth hormone (GH)) therapy. From January 2003 through August 2006, 1335 subjects were enrolled in the registry, approximately two-thirds of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::daa6d90da42701c89cfad6c11ebf3d74
https://pubmed.ncbi.nlm.nih.gov/18317441
https://pubmed.ncbi.nlm.nih.gov/18317441
Publikováno v:
ResearcherID
The need to assess correlation in settings where multiple measurements are available on each of the variables of interest often arises in environmental science. However, this topic is not covered in introductory statistics texts. Although several ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::307beab87d2d30740f17b26004d87802
https://hdl.handle.net/10453/26158
https://hdl.handle.net/10453/26158
